Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Illumina Aims For All-Inclusive Cancer Screen Via New Start-Up

This article was originally published in The Gray Sheet

Executive Summary

Genetic sequencing company Illumina is betting it can develop the first next-generation sequencing "pan-cancer" screening assay by building a separate company dedicated to the task. The new firm has $100 million in start-up funds and is called Grail.

You may also be interested in...

Big Pharma Helps Pour $900m Into Grail

The biggest venture funding round in history, pan-cancer screening test developer Grail has reeled in $900m in the first close of what it hopes will be a $1bn Series B round.

VC Deals Analysis: 2016 Bucks The Trend As Investment Dollars Dip

2016 was the year to break the bull run in venture investment activity, with total deal value and volume failing to surpass that of 2015. However, the IVD sector continued to be the most popular area for investment, and technologies that can help unravel the genomic puzzle behind diseases like cancer were the ones that attracted the big bucks last year and look likely to remain so in 2017.

Device/Diagnostics Quarterly Deal Statistics, Q1 2016

Device companies raised 50% more in Q1 2016 than the previous quarter, reaching $1.8 billion and led by debt offerings; diagnostic imaging acquisitions, such as Toshiba Medical Systems, were abundant. Diagnostics financings double in Q1, mostly from venture funding, including strong showing from liquid biopsy companies.

Related Content


Related Companies

Related Deals

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts